Vienna/Zurich, December 18, 2025 – Vaccentis AG – a Zurich-based biotech company specialising in cancer immunotherapy that recently opened its EU hub in Vienna – is adding two new healthcare experts to its Board of Directors: Mr Matt Regan and Dr Seng Chin Mah will join the board with immediate effect. This move aims to accelerate the development of an individualized cancer immunotherapy. With Mr Regan and Dr Mah, the Vaccentis Board of Directors – which previously consisted of Chairman Dr Matthias Oertle and members Subhasis Roy, Marcel Frei, Patrik Grandits and Martin Munte – now comprises a total of seven members.
“By expanding our Board of Directors, we are creating the optimal conditions to strengthen our company. Matt Regan and Dr Seng Chin Mah, with their broad and long-standing experience in the healthcare sector, are an excellent addition to our existing team. I am convinced that both can provide crucial support in our current phase,” says Vaccentis CEO Martin Munte.
Decades of expertise in the pharmaceutical sector
Matt Regan has over 30 years of pharmaceutical experience having worked across the entire value chain from manufacturing to commercial operations. Due to this broad experience, he has excellent insights into the entire pharmaceutical value chain. Regan is currently CEO of Micreos Pharmaceuticals and previously held significant roles in companies such as Abbott, Novo Nordisk, and AbbVie working across multiple countries. He is also currently on the Board of Micreos Pharmaceuticals (Switzerland), Portal Instruments (US) and Acrux Gold (UK).
Dr Seng Chin Mah has more than three decades of experience in the pharmaceutical and biotech industry, particularly in late-stage clinical development and regulatory approvals. He has worked for companies such as Novartis, Ciba and Canyon Pharmaceuticals, and is very well connected in the pharmaceutical and biotech scene. He is Chairman of BioVersys AG and a board member of OSR Holdings Inc.
Focus on the development of a precision immunotherapy
Vaccentis is currently developing VCC-001, an innovative immunotherapy against cancer: in this new therapeutic approach, tissue is taken from patients, purified, and an individualized immunotherapy is produced that detects and specifically attacks the tumour. Unlike other cancer immunotherapies, Vaccentis is focusing on proteins in its development, whereas competitors rely on mRNA. The initial focus is on renal cell carcinoma, with further indications to follow. According to current plans, the market launch of the VCC-001 drug candidate could already take place by the end of this decade.
About Vaccentis
Vaccentis AG is a company focused on the biotech and pharmaceutical sector based in Zurich/Switzerland. The Swiss pharmaceutical company focuses on the development of individual immunotherapies produced from the patient’s own tumor – initially for renal cell carcinoma, with further indications to follow. Approval for the EU and USA is expected in the coming years. Vaccentis is headed by CEO Martin Munte and Head of Research Ingrid Rauter, a management team with many years of experience. For further information, please visit vaccentis.com.
Press contact:
Brandenstein Communications
+43 1 319 41 01-11
presse@brandensteincom.at
Downloads:
Press Information